Ozempic Is About to Go Generic in India, China and Canada

Published by

rss.nytimes.com

on •1 min read

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.

Eli Lilly and Company Canada GLP-1 RAs (Drug)Obesity Drugs (Pharmaceuticals)Africa Developing Countries Diabetes Weight China

Learn more